Ensign Peak Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Ensign Peak Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$181K	Buy	49,314 +20,050	+69%	+$66.8K	﹤0.01%	1432
2026 Q1	$89.8K	Hold	29,264	–	–	﹤0.01%	1593
2025 Q4	$120K	Sell	29,264 -380,672	-93%	-$1.89M	﹤0.01%	1527
2025 Q3	$2M	Sell	409,936 -350	-0.1%	-$1.84K	﹤0.01%	800
2025 Q2	$2.08M	Hold	410,286	–	–	﹤0.01%	892
2025 Q1	$2.17M	Hold	410,286	–	–	﹤0.01%	870
2024 Q4	$2.77M	Buy	410,286 +1,300	+0.3%	+$8.74K	﹤0.01%	815
2024 Q3	$2.7M	Hold	408,986	–	–	﹤0.01%	827
2024 Q2	$3.07M	Buy	408,986 +10,050	+3%	+$87.7K	0.01%	765
2024 Q1	$3.98M	Buy	398,936 +11,421	+3%	+$127K	0.01%	695
2023 Q4	$3.82M	Buy	387,515 +172,545	+80%	+$1.23M	0.01%	697
2023 Q3	$1.64M	Buy	214,970 +45,750	+27%	+$456K	﹤0.01%	902
2023 Q2	$1.26M	Buy	+169,220	New	+$1.18M	﹤0.01%	1081
2022 Q4	–	Sell	-15,470	Closed	-$165K	–	2143
2022 Q3	$165K	Hold	15,470	–	–	﹤0.01%	1943
2022 Q2	$126K	Hold	15,470	–	–	﹤0.01%	1917
2022 Q1	$111K	Hold	15,470	–	–	﹤0.01%	2010
2021 Q4	$265K	Buy	+15,470	New	+$291K	﹤0.01%	1855

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Ensign Peak Advisors's RXRX Position: Q2 2026 in Review

Ensign Peak Advisors increased its Recursion Pharmaceuticals (RXRX) stake by 69% in Q2 2026, buying an estimated $66.8K and bringing the position to 49,314 shares worth $181K. The position accounts for ﹤0.01% of the portfolio, ranked #1432.

Ensign Peak Advisors first reported a position in RXRX in Q4 2021 and has held it in 17 quarters since. The position peaked at $3.98M in Q1 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Ensign Peak Advisors held 49,314 shares of Recursion Pharmaceuticals worth $181K as of Q2 2026.
Ensign Peak Advisors bought 20,050 Recursion Pharmaceuticals shares in Q2 2026, an estimated $66.8K.
Recursion Pharmaceuticals made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1432 holding.
Ensign Peak Advisors first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 17 quarters since.
Ensign Peak Advisors's Recursion Pharmaceuticals position peaked at $3.98M in Q1 2024.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.